4777 Article Views
Publication Date: 02 May 2008
Journal: Gene Regulation and Systems Biology
Department of Medicine, Hematology-Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, U.S.A.
Abstract
Colorectal cancer is the leading cause of cancer related deaths in the United States. Although it is preventable, thousands of lives are lost each year in the U.S. to colorectal cancer than to breast cancer and AIDS combined. In colon cancer, the formation and progression of precancerous lesions like aberrant crypt foci and polyps is associated with the up- regulation of cycloxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and hydroxy methyl glutaryl CoA reductase (HMG-CoA reductase). The current review will focus on the signaling pathway involving COX-2 and HMG-CoA reductase enzymes and their downstream effectors in signaling mechanism. Cancer cells need huge pools of both cholesterol and isoprenoids to sustain their unlimited growth potential. Cholesterol by modulating caveolae formation regulates several signaling molecules like AKT, IGFR, EGFR and Rho which are involved in cell growth and survival. Cholesterol is also essential for lipid body formation which serves as storage sites for COX-2, eicosanoids and caveolin-1. Experimental studies have identiļ¬ ed important mechanisms showing that COX-2, caveolin-1, lipid bodies and prenylated proteins is involved in carcinogenesis. Therefore multi-target, multi-drug approach is the ideal choice for effective colon cancer chemoprevention. This review will give an overview of the two pathways, their signaling networks, and the interactions between the components of the two networks in the activation and regulation of cell signaling involving growth/survival and explain the rationale for colon cancer chemoprevention using COX-2 inhibitors and statins.
Discussion
No comments yet...Be the first to comment.
My experience in publishing our manuscript in Environmental Health Insights was positive. The speed of processing was the fastest of all the journals I have encountered. The peer review and editorial comments were to-the-point and professional. The open reader access greatly enhances article visibility. I would publish again in this journal if I have suitable studies to publish.Dr Sue Ming (New Jersey Medical School, Newark, NJ, USA) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)